Myeloid neoplasm
MONDO:0005170Proliferation of myeloid cells originating from a primitive stem cell.
Also known as: myeloid malignancy, myeloid neoplasm, myeloid tumor, myeloid tumour
4453 clinical trials for this condition and its sub-types, 48 tagged with Myeloid neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Myeloid neoplasm
-
Myeloproliferative neoplasm 165 trials · 1,630 incl. sub-types
13 sub-types
- Myeloid leukemia 30 trials · 1,332 incl. sub-types Sub-types →
- Myelodysplastic/myeloproliferative neoplasm 80 trials · 233 incl. sub-types Sub-types →
- Primary myelofibrosis 191 trials · 195 incl. sub-types Sub-types →
- Myelofibrosis 149 trials
- Erythroid neoplasm 0 trials · 95 incl. sub-types Sub-types →
- Essential thrombocythemia 67 trials
- Therapy-related myeloid neoplasm 54 trials
- Myeloproliferative neoplasm, unclassifiable 11 trials · 16 incl. sub-types Sub-types →
- Transient myeloproliferative syndrome 13 trials
- Chronic neutrophilic leukemia 10 trials
- Chronic eosinophilic leukemia 9 trials
- Myeloproliferative disease, autosomal recessive 0 trials
- Thrombocytopenia 6 0 trials
-
Plasma cell myeloma 1,105 trials · 1,128 incl. sub-types
3 sub-types
- Smoldering plasma cell myeloma 63 trials · 64 incl. sub-types Sub-types →
- Non-secretory plasma cell myeloma 1 trial
- Osteosclerotic plasma cell myeloma 0 trials
-
Mast cell neoplasm 0 trials · 34 incl. sub-types
2 sub-types
- Mastocytosis 15 trials · 34 incl. sub-types Sub-types →
- Mastocytoma 0 trials Sub-types →
-
CD4+/CD56+ hematodermic neoplasm 31 trials
Most studied deeper sub-types
-
New hope for frail AML patients: stronger chemo regimens tested
Disease control CompletedThis study tests whether giving full-strength chemotherapy (either CPX-351 or a combination called CLAG-M) can help medically less-fit adults with acute myeloid leukemia live longer and achieve remission. About 60 participants will receive one of the two treatments. The goal is t…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New combo therapy aims to improve survival in aggressive leukemia
Disease control CompletedThis large phase III trial tested whether adding the drugs bortezomib and sorafenib to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) live longer without the cancer returning. Over 1,600 participants took part. The study focused on patients w…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Expanded cord blood transplant shows early promise for young cancer patients
Disease control CompletedThis study tested a new method of cord blood transplantation in 13 children and young adults with high-risk myeloid cancers. The approach uses a molecule called UM171 to grow more stem cells from a single cord blood unit, aiming to speed up recovery and reduce complications. Earl…
Phase 1/2 • Sponsor: ExCellThera inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo shows promise for tough blood cancers in early trial
Disease control CompletedThis early-stage study tested a new drug called PRT2527, alone or with other cancer drugs (zanubrutinib or venetoclax), in 86 people with various blood cancers that had returned or stopped responding to standard treatments. The main goals were to check safety, find the best dose,…
Phase 1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Boosting transplants with natural killers: new combo therapy aims to stop blood cancer return
Disease control CompletedThis study tested whether adding ready-made natural killer (NK) cells from a donor to a standard stem cell transplant could safely reduce the chance of cancer returning in people with high-risk myeloid cancers like acute myeloid leukemia, myelodysplastic syndrome, and chronic mye…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New hope: targeted pill may keep blood cancer in check after transplant
Disease control CompletedThis study tested the drug ivosidenib as a maintenance therapy for people with IDH1-mutant blood cancers (like AML) after a stem cell transplant. The goal was to find the safest dose and see if it could help prevent the cancer from coming back. 18 participants took the pill daily…
Phase 1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Can a phone app help older cancer patients get moving?
Symptom relief CompletedThis pilot study tested whether a mobile exercise app (GO-EXCAP) is feasible for older patients (60+) with myeloid neoplasms who are receiving chemotherapy. 25 participants used the app for 7 weeks. The goal was to see if patients would actually use the app and stick with the pro…
Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Blood cancer enzyme deficiency explored in new study
Knowledge-focused CompletedThis study looked at how often people with certain blood cancers or related conditions have an acquired deficiency of an enzyme called pyruvate kinase, which can cause anemia. Researchers took a single blood sample from 18 participants to measure enzyme activity and check for rel…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC